Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey

Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.Key words: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia.

📊

Temel Bulgular & Veri:Materials and methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia.

💡

Sonuç & Katkı:Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.Key words: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia. Materials and methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Results: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written. Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.Key words: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy

🔖

Bu Makaleye Atıf Yap

TAŞBAKAN, M. I., ERDEM, H. A., SAYINER, A., TAŞBAKAN, M. S., EKREN, P. K., YAMAZHAN, T., GÖKENGİN, D., ÇAĞLAYAN, D. (2022). Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 3, 912–920. https://ajindex.com/articles/611563

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty 2020; 9 (1): 29. doi:10.1186/s40249-020-00646-x 2. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy 2014; 58 (8): 4875-4884. doi: 10.1128/AAC.03011-14 3. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine 2017; 9 (396). doi:10.1126/scitranslmed.aal3653 4. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications 2020; 11 (1): 222. doi:10.1038/s41467-019-13940-6 5. Wang M, Cao R, Zhang L, Yang X, Liu J et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020; 30 (3): 269-271. doi:10.1038/s41422-020-0282-0 6. Yao X, Ye F, Zhang M, Cui C, Huang B et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020; 71 (15): 732-739. doi: 10.1093/cid/ ciaa237 7. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. Journal of Clinical Virology 2004; 31 (1): 69-75. doi:10.1016/j.jcv.2004.03.003 8. Chan JF, Yao Y, Yeung ML, Deng W, Bao L et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. The Journal of Infectious Diseases 2015; 212 (12): 1904-1913. doi:10.1093/infdis/jiv392 9. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences 2020; 50 (SI-1): 611-619. doi:10.3906/sag-2004-145 10. Chen J, Liu D, Liu L, Liu P, Xu Q, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Journal of Zhejiang University (Medical Science) 2020; 49 (2):